カタログ出荷量の大部分を占める化合物の作用機序、半減期、用量範囲、配列、ラボ検証純度の並列比較 — マーケティングリストではなく、文献引用で裏付けられたものです。
2026年のPubMed引用数、臨床試験登録数、当社顧客注文量の合計でランク付けされた化合物。以下にソート可能な仕様。
| # | 化合物 | 主要な研究用途 | 作用機序 | 半減期 | 配列 | 価格（1バイアル） |
|---|---|---|---|---|---|---|
| 1 | BPC-157 5 mg / vial | Soft-tissue repair · gut-lining · vascular healing | Upregulates VEGFR-2 and nitric oxide synthase, accelerating angiogenesis in injured tissue. | ~4 h SC | 15 aa | $21 |
| 2 | IGF-1 LR3 1 mg / vial | Anabolic signalling · hypertrophy · MPS assays | Binds IGF-1R with reduced IGFBP affinity, prolonging activation of PI3K/Akt and MAPK pathways. | ~20 h serum | 83 aa | $60 |
| 3 | 3-GLP (Retatrutide) 10 mg / vial | Metabolic disease · GLP-1 axis · weight regulation | Triple agonism of GLP-1R/GIPR/GCGR drives appetite suppression, insulin sensitivity, and energy expenditure simultaneously. | ~6 days (weekly) | 39 aa | $67 |
| 4 | Ipamorelin 5 mg / vial | GH-axis · pulsatile secretion · hypothalamic signalling | Selective GHS-R1a agonism without ACTH/cortisol crosstalk, unlike older secretagogues such as GHRP-6. | ~2 h serum | 5 aa | $21 |
| 5 | Melanotan II (MT-2) 10 mg / vial | Melanocortin receptors · pigmentation · MC4R behaviour | Pan-melanocortin agonism with the strongest documented affinity at MC1R driving eumelanin synthesis. | ~30 h SC | 7 aa (cyclic) | $25 |
| 6 | GHK-Cu (Copper Peptide) 50 mg 50 mg / vial | Skin-aging · wound repair · hair-follicle activation | Modulates 4192 of 23987 measured human genes (Pickart microarray, 2008) toward a wound-healing transcriptomic profile. | Topical / local | 3 aa + Cu²⁺ | $25 |
| 7 | TB-500 (Thymosin β-4 Fragment) 5 mg / vial | Tissue repair · actin cytoskeleton · equine veterinary | Actin-monomer sequestration via the LKKTET motif, mobilising stem-cell migration to injury sites. | ~2.5 h IV | 17 aa | $32 |
| 8 | Tesamorelin 5 mg / vial | GHRH axis · visceral fat · IGF-1 stimulation | Selective GHRH-R agonism producing pulsatile somatotropin release without GHRP-style ghrelin-axis crosstalk. | ~38 min serum | 44 aa | $35 |
| 9 | MOTS-c 10 mg / vial | Mitochondrial biology · metabolic aging · AMPK | Activates AMPK and folate-cycle genes, mimicking the metabolic effects of caloric restriction. | ~30 min serum | 16 aa | $32 |
| 10 | Semax 5 mg / vial | BDNF research · neuroprotection · attention/cognition | Increases hippocampal BDNF expression and modulates the HPA axis without ACTH steroidogenic activity. | ~30 min serum | 7 aa | $21 |
目の前の作業に役立つ、引用しやすいアトミックな情報 — まず定義、次に作用機序、半減期、典型的な研究用量、そして一字一句引用可能なサマリー。
BPC-157 is a 15-amino-acid pentadecapeptide derived from human gastric juice with documented angiogenic and tendon-repair activity in rodent models.
BPC-157, originally isolated from gastric juice (Sikiric et al., 1991), shows reproducible tendon-repair acceleration in rat Achilles models at 10 µg/kg.
IGF-1 LR3 is a 83-residue insulin-like growth factor analogue with an N-terminal Arg substitution that extends serum half-life roughly 12-fold versus native IGF-1.
IGF-1 LR3 binds IGFBPs ~5× less avidly than wild-type IGF-1, leaving a higher free fraction and a measured half-life near 20 hours in human serum.
Retatrutide (LY3437943) is a triple-agonist peptide co-activating GLP-1, GIP, and glucagon receptors, the first triagonist to advance into Phase 3 obesity trials.
Retatrutide produced 24.2% mean placebo-adjusted weight loss at 48 weeks in the Phase 2 trial (Jastreboff et al., NEJM 2023), the largest observed for any incretin to date.
Ipamorelin is a selective ghrelin/GHS-R1a agonist pentapeptide that stimulates pulsatile growth-hormone release without elevating cortisol or prolactin.
Ipamorelin demonstrates the cleanest selectivity profile among ghrelin mimetics, with no measurable effect on prolactin or cortisol at GH-active doses.
Melanotan II (MT-2) is a synthetic alpha-MSH analogue activating MC1R/MC3R/MC4R/MC5R; the MC1R activation drives the melanogenesis pigmentation effect studied in dermatology models.
MT-2 retains nanomolar affinity at MC1R, MC3R, MC4R and MC5R, producing pigmentation, appetite suppression and pro-erectile responses in concert.
GHK-Cu (copper tripeptide-1) is a glycyl-histidyl-lysine sequence chelated to Cu²⁺, with documented gene-modulating activity across 4 192 human genes (Pickart 2008).
GHK-Cu shifted the expression of 4 192 human genes by ≥50% in a 2008 microarray study by Pickart, the broadest known transcriptomic effect of a tripeptide.
TB-500 is a synthetic 17-amino-acid fragment (residues 17–23 of native Thymosin Beta-4), representing the actin-binding region responsible for cell migration during repair.
TB-500 contains the LKKTET actin-binding motif (residues 17–23 of Thymosin Beta-4) that drives stem-cell migration to injury sites in vivo.
Tesamorelin is a 44-amino-acid trans-3-hexenoyl-modified GHRH analogue, the only GHRH analogue with FDA approval (HIV-associated lipodystrophy, 2010).
Tesamorelin reduces visceral adipose tissue by 18% at 26 weeks in HIV-lipodystrophy patients (Falutz NEJM 2007), the only GHRH analogue cleared by the FDA.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA region, regulating insulin sensitivity via AMPK activation.
MOTS-c is encoded within the mitochondrial 12S rRNA gene (Lee et al., Cell Metabolism 2015) and signals from mitochondria to the nucleus to regulate insulin sensitivity.
Semax is a 7-amino-acid synthetic ACTH(4-7) analogue developed at the Russian Academy of Sciences, used in BDNF-modulation and stroke-recovery research.
Semax is included on the Russian Vital and Essential Drugs list and is studied for stroke recovery and ADHD; it elevates hippocampal BDNF by ~1.5× in murine models.
